JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

J&J has already benefitted from Halozyme’s ENHANZE tech with DARZALEX, and it looks as if OPDIVO might be another blockbuster drug that could benefit from ENHANZE tech. Essentially, Halozyme offers ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

"According to the latest BCC research study, the demand for Global Oncology Pharmaceuticals Market increased from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth ...

Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a third time and ...

Wall St. Insights The seemingly endless political season is almost over. It’s possible we won’t know the winner for a while.

Last month, the US Food and Drug Administration (FDA) approved three new drugs, as well as a potentially practice-changing ...

Tensions flared in Belagavi, Karnataka, after a poster depicting Mughal emperor Aurangzeb as the "real founder of Akhand Bharat" was removed by police. The poster, installed by unidentified youths ...

Dozens of candidates are running in the 2024 presidential election apart from Kamala Harris and Donald Trump, which may influence the final result in the tight race. None is on a realistic path to the ...

Sydney’s west has seen an explosion of development in the past 20 years. Its latest project is the one we can be most proud of.